Overview
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials
Written by: Yves Dauvilliers, M.D.Emmanuel Mignot, M.D.Jakub Antczak, M.D.Isabelle Arnulf, M.D.Lucie Barateau, M.D.Erik Buntinx, M.D.Bruce Corser, M.D.Alex Iranzo, M.D., Ph.D.Ramin Khatami, M.D.Gert Jan Lammers, M.D.Katharina Lederer, M.D.Kristian Bernhard Nilsen, M.D., Ph.D.Fabio Pizza, M.D.Markus H. Schmidt, M.D.Sheila Sivam, M.D., Ph.D.Oliver Sum-Ping, M.D.Mitsutaka Taniguchi, M.D.Shuqin Zhan, M.D.Anson Abraham, Ph.D.Alice Cai, M.D.Yeting Du, Ph.D.Mark R. Etherton, M.D., Ph.D.Helene Faessel, Pharm.D, Ph.D.Samuel Hsiao, Ph.D.Harisha Kadali, M.D.Elena Koundourakis, Ph.D.Melissa Naylor, M.D., Ph.D.Rachel Neuwirth, M.S.Tina Olsson, Ph.D.Raquel Rogers, M.D.Sarah Sheikh, B.M., B.Ch.Shinichiro Tanaka, Ph.D.Philipp von Rosenstiel, M.D.Christian von Hehn, M.D., Ph.D.Yaming Hang, Ph.D.Baiyun Yao, Ph.D.Rafael del Rio Villegas, M.D., Ph.D.Giuseppe Plazzi, M.D.
Find these authors on Roon
